Product Description
AqT® Biotin Reduced Thiol-Labeled Trastuzumab is a novel biotinylated Trastuzumab developed with CellMosaic's proprietary AqueaTether® (AqT®) linker technology, delivering enhanced assay performance.
| Download Documents | |
|---|---|
| Product Sheet | |
| SDS | COA (Lot S702.S11.0701F) |
Biotin is highly hydrophobic and only sparingly soluble in water. These properties make it difficult to achieve high biotin loading on a biopolymer. Most conventional biotinylation reagents require significant amounts of organic solvent, which can promote protein aggregation, precipitation, and loss of activity during labeling. CellMosaic’s proprietary AqT® linker converts biotin into a highly water-soluble reagent, enabling high biotin loading with minimal or no organic solvent.
Trastuzumab is a humanized IgG1κ monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2/ErbB2). Trastuzumab is the antibody component of HER2-targeted antibody–drug conjugates such as ado-trastuzumab emtansine and trastuzumab deruxtecan. Biotinylated trastuzumab can be used as a research reagent for HER2 studies and diagnostic assay development. Potential biotin–avidin-based applications include ELISA, flow cytometry, immunohistochemistry (IHC), immunocytochemistry (ICC), immunoprecipitation (IP), pull-down assays, biosensor and surface-immobilization applications, cell isolation, and magnetic separation.
This product is sold as 1 tube each of 100µg (CM86169-5100UG) and 500 µg (CM86169-500UG). For bulk quantities and custom packaging requirements, please contact us for pricing and availability.
For a detailed description of the AqT® technologies, please see our technology section.
Key Features
- Lyophilized powder; ready for use after reconstitution with water. No additional buffer is required.
- High biotin loading with an average of 6–8 Biotin molecules per trastuzumab molecule.
- Protein content accurately determined by UV/HPLC analysis; biotin incorporation levels determined by biotin assay.
- Advanced AqT® linker technology: Utilizes CellMosaic’s proprietary, super-hydrophilic, water-soluble, charge-neutral AqT® linker to enhance aqueous solubility and minimize aggregation.
Applications
- HER2 detection and quantification
- HER2 binding and competition assays
- Selection and capture of HER2-positive cells
- Affinity purification and pull-down assays for HER2 and associated protein complexes
- HER2 receptor internalization studies
- Targeted imaging of HER2-positive cells and tumors
- HER2-targeted delivery research
- Assay development and quality control for HER2-expressing cell lines, biosensors, diagnostic assay-development platforms, and HER2-targeted formulations
Specifications
- Physical Appearance: White to off-white preservative-free lyophilized powder.
- Storage Temp: –20°C or below.
- Purity: ≥95% of monomeric by SEC-HPLC (refer COA of each lot for actual value).
- Amount of Biotin Loaded per BSA Molecule: 6–8 (refer COA of each lot for actual value).
Characterization of AqT® Biotin-Trastuzumab Product by HPLC
Lot Number: S702.S11.0701F (Biotin Loading: 6.9 by Biotin Assay)
Figure 1. Overlay SEC-HPLC profiles of trastuzumab (before labeling, blue trace) and AqT® Biotin Trastuzumab (red trace) in citrate buffer, demonstrating ≥99% monomeric purity with no detectable aggregates.
Note: SEC separates the conjugates by apparent MW or size in aqueous solution. In general, higher-MW species elute earlier. SEC is also a useful tool for assessing the level of aggregation in a biopolymer. By comparing the SEC profiles of an unlabeled protein and labeled protein, you can estimate the extent of aggregation in the labeled protein.
Figure 2. Overlay HIC-HPLC profiles of trastuzumab (before labeling, blue trace) and AqT® Biotin Trastuzumab after labeling (red trace) in citrate buffer, showing only a slight hydrophobic shift and a high degree of antibody homogeneity.
Note: HIC separates conjugates based on hydrophobicity. In general, more hydrophilic species elute earlier. HIC is also a useful tool for assessing the degree of heterogeneity in a biopolymer. Comparing the HIC profiles of an unlabeled antibody and a labeled antibody allows changes in the hydrophobicity and heterogeneity of the labeled antibody to be evaluated.
Frequently Asked Questions:
If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.
Other Details
The information in this document is subject to change without notice. CellMosaic® assumes no responsibility for any errors or omissions that may appear in this document. Under no circumstances shall CellMosaic be liable, whether in contract, tort, warranty, or under any statute or on other legal theory, for special, incidental, indirect, punitive, multiple, or consequential damages related to or arising from this document, including but not limited to the use of this product thereof.CellMosaic’s products, including but not limited to AqT®, NeIon™, oxLink™ and sxLink™ (collectively, the “Products”), are covered by, or are the subject of, one or more issued patents and pending patent applications, including without limitation: 9,688,663 B2; 8,907,079 B2; 9,511,150 B2; 9,907,854 B2; 9,346,833 B2; 9,518,067 B2; CN104066451B; CN107043339B; CA 2,841,313; EP 2734238 B1; AU2012284055; JP 6240599 B2; and corresponding foreign patents and patent applications. The purchase of the Product conveys solely a limited, non-exclusive, non-transferable, non-sublicensable license to use the Product only for the purchaser’s internal research and development purposes. No right or license is granted, either expressly or by implication, estoppel, or otherwise, under any patent, trademark, copyright, or other intellectual property right of CellMosaic, except as expressly stated herein. Any commercial use of the Product is strictly prohibited without a separate written agreement from CellMosaic. Prohibited commercial uses include, without limitation: (a) the sale, lease, licensing, distribution, or other transfer of the Product or any materials derived from or produced using the Product; (b) the sale, lease, licensing, or other grant of rights to use the Product or any materials derived from or produced using the Product; and (c) the use of the Product to perform services for a fee or other consideration for third parties, including without limitation contract research, screening services, or diagnostic or therapeutic applications. For information regarding commercial licensing or collaboration, please contact us at info@cellmosaic.com.
